Skip to main content
Article thumbnail
Location of Repository

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a\ud distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network

By K. Farrell, P. McKay and M. Leach


Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL). Management of NLPHL remains controversial. In a 14-year multicenter series, 69 cases were analyzed, and the median follow-up was 53 months (range 11–165.) B-symptoms were present in only 4.3% of patients, and 81.1% of patients had stage I/II disease. Treatment was with radiotherapy (53.6%), chemotherapy (21.7%), combined modality (17.4%), and observation (7.2%). In all, 10.1% of patients relapsed and 2.9% of patients developed high-grade transformation to DLBCL. All relapses and transformations were salvageable. No patient died of their disease. The 5-year relapse-free survival was 92%, transformation-free survival 98.4%, and overall survival 100%. We conclude that NLPHL behaves as a distinct clinical entity, often presenting at an early stage without risk factors. It has an excellent outcome. It may be possible, in early-stage disease, to reduce the intensity of therapy in NLPHL, to single-modality radiotherapy, without affecting OS

Topics: R1
Publisher: Informa Healthcare
Year: 2011
OAI identifier:
Provided by: Enlighten

Suggested articles

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.